New drug trial aims to help rare immune disorder
NCT ID NCT04097561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether belimumab is safe for people with idiopathic CD4 lymphopenia (ICL), a rare condition causing low CD4 white blood cells and increased infection risk. About 20 adults aged 18-70 with ICL and autoantibodies will receive 8 doses of belimumab intravenously over several weeks. The goal is to check for side effects and see how the drug affects immune cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.